Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AN2025 and AN0025 with Atezolizumab in Advanced Solid Tumors
NCT04975958Phase 1Completed
- Sponsor
- Adlai Nortye
- Start
- Sep 2021
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of buparlisib and palupiprant in solid tumor (advanced stage) (3 arms), sponsored by Adlai Nortye. Primary endpoints: Dose Limiting Toxicities at 3 weeks and Adverse Events and Serious Adverse Events at 2 years. Started Sep 2021; status: completed.
02
Drugs
buparlisibpalupiprant
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04975958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04975958.